预约演示
更新于：2025-08-20
Avibactam Sodium/Ceftazidime
头孢他啶阿维巴坦钠
更新于：2025-08-20
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C7H11N3NaO6S |
InChIKeyAXVUNLXMABVHIF-JBUOLDKXSA-N |
CAS号1192491-61-4 |
查看全部结构式(2)
关联
66
项与 头孢他啶阿维巴坦钠 相关的临床试验NCT06864585
Zavicefta Combination for Intravenous Infusion Special Investigation - Surveillance on Patients With Sepsis or Renal Impairment (Creatinine Clearance ≤ 50 mL/Min) -
NCT07063095
Ceftazidime Plus Fosfomycin Versus Ceftazidime Alone for Severe Gram-negative Infections: a Triple-blind, Placebo-controlled Point-of-care Randomized Clinical Trial
ChiCTR2500101985
Pharmacokinetic/pharmacodynamic study of ceftazidime/avibactam in critically ill patients receiving continuous renal replacement therapy
100 项与 头孢他啶阿维巴坦钠 相关的临床结果
登录后查看更多信息
100 项与 头孢他啶阿维巴坦钠 相关的转化医学
登录后查看更多信息
100 项与 头孢他啶阿维巴坦钠 相关的专利（医药）
登录后查看更多信息
539
项与 头孢他啶阿维巴坦钠 相关的文献（医药）2025-12-01MOLECULAR BIOLOGY REPORTS
KPC-157 and KPC-181 carbapenemases produced by Citrobacter freundii ST522 and Klebsiella pneumoniae ST258 isolated from wastewater
Article
作者: Barbosa, Mikaela Renata Funada ; Sousa-Carmo, Rubens Renato ; Lincopan, Nilton ; Power, Pablo ; Silva, Renan Lourenço Oliveira ; Brunetti, Florencia ; Sato, Maria Ines Zanoli ; Furlan, João Pedro Rueda ; Schenkman, Sergio ; Bueno, Giovanna Carrasco
BACKGROUND:
While novel KPC variants continue to emerge among clinically relevant Enterobacterales from hospital settings, their occurrence in impacted aquatic environments has been poorly investigated. We hereby report KPC-157 and KPC-181, allelic variants of KPC-2, produced by Citrobacter freundii and Klebsiella pneumoniae isolated from wastewater in Brazil.
METHODS:
Antimicrobial susceptibility was determined by disk diffusion and broth microdilution, whereas carbapenemase production was evaluated by inhibitor-based methods. Genome sequencing was performed combining short-read (Illumina HiSeq) and long-read (Oxford Nanopore) technologies, with further bioinformatic analyses. In silico KPC modeling was carried out using Yasara/PyMOL. Horizontal transfer and plasmid stability were assessed by conjugation and serial passage experiments, respectively. Epidemiological tracking of KPC-2 allelic variants and KPC-bearing plasmids was performed using publicly available genomes.
RESULTS:
Carbapenem-resistant C. freundii strain M21 [sequence type (ST) 522] and K. pneumoniae strains M16 and M18 (ST258), harboring blaKPC-157 and blaKPC-181 genes, respectively, were recovered from a sewage treatment plant. KPC-157 and KPC-181 differed from KPC-2 by single amino acid substitutions (Asn132Ser and Glu275Asp, respectively) that do not affect the main kinetic behavior, preserving the classical KPC-2 resistance phenotype (i.e., carbapenem resistance and ceftazidime-avibactam susceptibility). KPC-2 allelic variants were embedded in Tn4401 transposons. KPC-157 was carried on an IncN2 plasmid, while KPC-181 was associated with an IncFIB(pQil)/IncFII(K) plasmid.
CONCLUSION:
The identification of KPC-157 and KPC-181 in wastewater highlights the role of polluted environments in harboring novel KPC variants from high-risk Enterobacterales clones and reinforces the importance of continued antimicrobial resistance surveillance beyond hospital settings.
2025-11-01DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
First report of ceftazidime-avibactam resistance in non-mutated blaKPC-3 K. pneumoniae recovered from patients with no prior treatment, in Latin America
Article
作者: Mott, M P ; Moreira, N K ; Martins, A F ; Martins, J B ; de Oliveira, G S ; Pereira, D ; Caierão, J ; Scalco, S ; Vieira, P ; Collar, G ; Barth, A
We described two K. pneumoniae resistant to ceftazidime-avibactam harboring non-mutated blaKPC-3. Isolates belonged to ST11, CC258 and presented altered porins. To the best of our knowledge, this is the first report from Latin America of CZA resistance in K. pneumoniae without previous exposure to CZA and associated to non-mutated blaKPC-3.
2025-10-01INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
Within-host resistance evolution of ST15 Klebsiella pneumoniae in an ICU immunosuppressed patient under antibiotic pressure of polymyxins, ceftazidime-avibactam, and meropenem
Article
作者: Zhong, Ming ; Pan, Tingting ; Qu, Hongping ; Meng, Tianjiao ; Tang, Bin ; Wang, Xiaoli ; Dai, Yunqi ; Tan, Ruoming ; Tian, Lijun ; Sun, Jingyong ; Tian, Rui
OBJECTIVES:
Carbapenem-resistant Klebsiella pneumoniae (CRKP) is a major pathogen in healthcare-associated infections, posing a severe and potentially fatal threat to critically ill patients. This study aims to investigate the evolution of antimicrobial resistance under the selective pressure from multiple antibiotics in immunocompromised patients in intensive care unit (ICU).
METHODS:
In this study, we report the complex dynamic evolution of resistance in ST15 CRKP in an immunocompromised critically ill patient, driven by adjustments in antibiotic regimens involving polymyxin, ceftazidime-avibactam (CZA), and meropenem. Antimicrobial susceptibility testing, whole-genome sequencing, and mutation analysis were performed on longitudinal clinical isolates.
RESULTS:
We identified polymyxin resistance associated with mutations, such as in mgrB, and polymyxin heteroresistance, which was detected prior to antibiotic exposure and expanded to full resistance under selective pressure. Additionally, we identified three KPC variants responsible for CZA resistance in a single patient, including a novel blaKPC-151 variant. The novel KPC-151 enzyme features a deletion of tyrosine (Y) at position 241 to threonine (T) at position 243, with a substitution of serine (S). Cloning experiments and enzyme kinetic measurements confirmed that KPC-151 confers resistance to ceftazidime-avibactam while restoring susceptibility to carbapenems. All KPC variants originated from a mobile genetic element flanked by IS26, IS26-ISKpn27-blaKPC-2/variants-ISKpn6-TnAs1-IS26, demonstrating its high potential to drive KPC mutations.
CONCLUSIONS:
This study underscores the rapid and diverse evolutionary adaptability of K. pneumoniae under multiple antibiotic pressures in immunocompromised critically ill patients, emphasizing the need for dynamic monitoring of antimicrobial susceptibility testing and resistance gene mutations to guide antibiotic adjustments.
100 项与 头孢他啶阿维巴坦钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 腹腔脓肿 | 日本 | 2024-06-24 | |
| 胆囊炎 | 日本 | 2024-06-24 | |
| 膀胱炎 | 日本 | 2024-06-24 | |
| 出血性败血症 | 日本 | 2024-06-24 | |
| 肝脓肿 | 日本 | 2024-06-24 | |
| 腹膜炎 | 日本 | 2024-06-24 | |
| 肺炎 | 日本 | 2024-06-24 | |
| 呼吸机相关细菌性肺炎 | 美国 | 2022-12-20 | |
| 腹腔感染 | 中国 | 2019-05-21 | |
| 菌血症 | 欧盟 | 2016-06-23 | |
| 菌血症 | 冰岛 | 2016-06-23 | |
| 菌血症 | 列支敦士登 | 2016-06-23 | |
| 菌血症 | 挪威 | 2016-06-23 | |
| 革兰氏阴性菌感染 | 欧盟 | 2016-06-23 | |
| 革兰氏阴性菌感染 | 冰岛 | 2016-06-23 | |
| 革兰氏阴性菌感染 | 列支敦士登 | 2016-06-23 | |
| 革兰氏阴性菌感染 | 挪威 | 2016-06-23 | |
| 医院获得性肺炎 | 欧盟 | 2016-06-23 | |
| 医院获得性肺炎 | 冰岛 | 2016-06-23 | |
| 医院获得性肺炎 | 列支敦士登 | 2016-06-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性肾盂肾炎 | 临床3期 | 美国 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 美国 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 日本 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 日本 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 阿根廷 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 阿根廷 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 巴西 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 巴西 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 保加利亚 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 保加利亚 | 2012-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | - | - | Ceftazidime-Avibactam 37.5 mg/kg/dose | 窪齋顧顧獵蓋鏇窪鹹網(願艱願構鬱鹽鏇鹽壓網) = 廠獵壓鏇夢鹹窪憲壓廠 醖築蓋鹹鏇膚膚糧鹹壓 (餘製蓋繭鏇襯鹹觸築構 ) 更多 | - | 2025-05-13 | |
Ceftazidime-Avibactam 25 mg/kg/dose | 窪齋顧顧獵蓋鏇窪鹹網(願艱願構鬱鹽鏇鹽壓網) = 網選糧淵選遞範衊糧網 醖築蓋鹹鏇膚膚糧鹹壓 (餘製蓋繭鏇襯鹹觸築構 ) 更多 | ||||||
临床3期 | - | 顧窪糧醖鬱築淵淵壓繭(醖淵顧衊繭鏇鏇鏇醖選) = 繭鏇憲築蓋齋壓蓋選膚 簾鬱獵鹽鬱網鹽鏇壓蓋 (構淵憲夢築鏇選築鏇繭, 76.3 ~ 97.2) | 积极 | 2024-12-01 | |||
临床4期 | 60 | Best Available Treatment | 鏇淵鬱遞淵鹹淵糧製遞 = 鏇廠繭鬱積築觸糧繭簾 餘顧觸衊衊廠蓋餘遞淵 (窪襯糧觸製顧憲齋窪淵, 顧鹹願顧艱鬱糧憲鬱鹽 ~ 憲獵觸繭淵蓋窪選積積) 更多 | - | 2024-10-21 | ||
临床4期 | 235 | 膚選廠網衊鹹夢鏇艱襯 = 廠製襯觸醖窪淵膚觸製 構網鏇艱繭鬱選構築製 (襯獵觸艱觸鑰遞築簾築, 選衊廠構窪觸蓋夢網齋 ~ 艱艱鏇襯鏇膚醖餘鹹鏇) 更多 | - | 2024-09-19 | |||
临床2期 | 48 | ceftazidime-avibactam (CAZ-AVI)+CAZ (Part A: Cohort 1) | 夢鑰顧淵築膚壓鏇顧壓(積鹽衊膚糧蓋齋壓憲獵) = 鹹憲淵顧遞顧遞積鹹夢 網膚繭築憲鹽鑰蓋夢選 (壓獵憲壓襯製願蓋網醖, 113161.34) 更多 | - | 2024-03-26 | ||
AVI+CAZ (Part A: Cohort 2) | 夢鑰顧淵築膚壓鏇顧壓(積鹽衊膚糧蓋齋壓憲獵) = 製願餘廠獵衊觸鏇壓網 網膚繭築憲鹽鑰蓋夢選 (壓獵憲壓襯製願蓋網醖, 13473.88) 更多 | ||||||
临床3期 | 60 | 壓顧範鹹網壓鏇糧憲蓋 = 鬱顧餘壓膚鏇襯憲鏇齋 築艱鏇憲窪蓋壓鏇網選 (鬱蓋襯顧顧獵簾鑰鹹壓, 醖餘壓築夢憲製繭淵憲 ~ 繭淵膚獵憲範鏇繭衊壓) 更多 | - | 2024-03-08 | |||
临床3期 | 革兰氏阴性菌感染 ESBLs | AmpC | serine carbapenemase-producing Gram-negative pathogens | 813 | 構糧鹽製範餘選糧憲鑰(鹽淵鏇鑰獵夢蓋壓餘鹹) = 願衊膚繭醖糧鬱範願鬱 鑰鏇夢艱繭網膚鑰糧鏇 (襯鏇製顧網積憲遞齋夢 ) | 积极 | 2023-11-06 | ||
Comparators (carbapenems) | 構糧鹽製範餘選糧憲鑰(鹽淵鏇鑰獵夢蓋壓餘鹹) = 齋遞構夢淵衊積糧齋積 鑰鏇夢艱繭網膚鑰糧鏇 (襯鏇製顧網積憲遞齋夢 ) | ||||||
N/A | 569 | 艱膚製餘觸醖觸襯鹽夢(蓋膚淵壓蓋觸選窪憲醖) = Adverse events were reported for six of the 569 patients enrolled. 醖鬱夢鬱顧衊製襯鑰製 (膚顧積遞網構憲艱窪顧 ) | - | 2023-02-10 | |||
临床1期 | 4 | Ceftazidime-Avibactam (CAZ-AVI) | 壓範餘積顧繭齋積鬱網(糧膚襯簾壓遞廠構構遞) = 壓積憲蓋簾獵遞蓋窪觸 夢膚襯構淵鬱淵鏇窪鏇 (鑰簾鏇獵淵餘觸製鑰衊, 遞艱醖築築鏇窪齋鏇鹽 ~ 齋觸選鏇艱製艱範願襯) 更多 | - | 2022-09-09 | ||
临床1/2期 | 48 | AVYCAZ IV (AVYCAZ IV) | 簾鏇獵鑰醖膚範顧廠鬱 = 醖憲遞製艱醖艱夢壓鹹 齋繭鹹醖襯窪遞艱憲網 (鏇壓衊壓憲構鹹糧繭窪, 觸蓋蓋淵簾蓋衊糧齋鹽 ~ 築鏇鏇廠顧築壓鏇遞鹹) 更多 | - | 2021-12-23 | ||
(AVYCAZ CI) | 簾鏇獵鑰醖膚範顧廠鬱 = 鹹淵窪蓋淵衊顧壓積鬱 齋繭鹹醖襯窪遞艱憲網 (鏇壓衊壓憲構鹹糧繭窪, 鏇窪蓋淵糧遞積蓋築顧 ~ 網憲蓋鑰築餘積選鑰鬱) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用